RIBOMIC Inc.【JP:4591】Stock Price

Ribomics is a biotech venture company specializing in research and development of aptamer-based pharmaceuticals, which are expected to be next-generation drugs. The company advances innovative aptamer drug development using its proprietary "RiboART System." Ribomics' corporate mission is to "address unmet medical needs," with a particular focus on achieving clinical proof of concept for its own candidates.

Ribomics is developing umedaptanib pegol, an aptamer drug, for the treatment of achondroplasia (ACH) and wet age-related macular degeneration (wet AMD). For ACH, the company is conducting clinical trials with support from the Japan Agency for Medical Research and Development (AMED) and has achieved certain milestones. For wet AMD, the company is evaluating the efficacy and safety of umedaptanib pegol through clinical trials in the United States.

Ribomics is also developing other aptamers, including RBM-006 and RBM-011, targeting proliferative vitreoretinopathy and pulmonary arterial hypertension. The company has developed AI-powered aptamer discovery technologies, "RaptRanker" and "RaptGen," to streamline the drug discovery process. These tools enable rapid and accurate aptamer identification, accelerating research and development timelines.

Ribomics' business model consists of two operations: in-house drug discovery and collaborative research. The company aims to license out aptamers developed internally to pharmaceutical companies and earn licensing fees. Additionally, the company generates revenue through collaborative research partnerships with pharmaceutical firms. This dual approach supports revenue stability and builds expertise in drug development.

Ribomics aims to establish aptamer pharmaceuticals as the next-generation drug class following monoclonal antibodies. Compared to antibody drugs, aptamers offer advantages including lower manufacturing costs and easier chemical modification, with particular potential in treating ophthalmic diseases. Ribomics leverages these characteristics to advance aptamer drug development.

Ribomics is committed to addressing unmet medical needs in disease areas through aptamer drug research and development. The company advances innovative aptamer therapeutics using its "RiboART System." It prioritizes ethical practices, conducts research based on cutting-edge science, and aims to maximize corporate value.

Ribomics' growth strategy focuses on generating revenue through early licensing-out of aptamers and advancing its own clinical development. The company is conducting clinical trials using umedaptanib pegol to achieve early revenue generation. It also strengthens partnerships with pharmaceutical companies through collaborative research to realize continuous licensing-out opportunities.

As medium to long-term growth objectives, the company aims to transition from discovery to clinical stages, develop next-generation aptamer technologies, and create corporate value for society. This positions Ribomics to establish a leading role in aptamer drug development. The company is particularly focused on building a high-quality proprietary pipeline and developing novel technologies.

Ribomics seeks to establish aptamer therapeutics as a next-generation pharmaceutical category following monoclonal antibodies in the market. Aptamer drugs offer advantages including reduced manufacturing costs and ease of chemical modification, with particular potential demonstrated in treating ophthalmic diseases. Leveraging these characteristics, the company is advancing aptamer drug development.